Impact of genetic polymorphisms in the interleukin-18 and interleukin-21 genes on the risk and clinical outcomes of multiple sclerosis - Scorecard - MDSpire
Advertisement
Impact of genetic polymorphisms in the interleukin-18 and interleukin-21 genes on the risk and clinical outcomes of multiple sclerosis
Clinical Scorecard: Influence of Genetic Variants in Interleukin-18 and Interleukin-21 on Multiple Sclerosis Risk and Clinical Outcomes
At a Glance
Category
Detail
Condition
Key Mechanisms
Genetic variants in IL-18 and IL-21 cytokines influence susceptibility and clinical outcomes of MS. [Source needed]
Target Population
Care Setting
Key Highlights
First study in Egypt analyzing these genetic variants in MS. [Source needed]
Guideline-Based Recommendations
Diagnosis
Clinically confirmed MS according to McDonald criteria. [Source needed]
Management
Assessment of disability using Kurtzke’s EDSS and disease severity with MSSS. [Source needed]
Monitoring & Follow-up
Retrospective collection of demographic and clinical data. [Source needed]
Risks
Exclusion of patients with chronic inflammatory disorders, other autoimmune diseases, chronic kidney disease, liver disease, current pregnancy, or psychiatric diseases. [Source needed]
Patient & Prescribing Data
Genetic polymorphism investigations are necessary for understanding MS risk and progression. [Source needed]
Clinical Best Practices
Informed consent obtained from all participants. [Source needed]
Ethical approval from Institutional Review Board (IRB). [Source needed]
Use of standardized methods for DNA extraction and SNP analysis. [Source needed]
